These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 606412)

  • 1. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA
    Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 5. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy.
    Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R
    Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ; Houston IB
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 1 alpha-hydroxyvitamin D3 on experimental uremic renal osteodystrophy in rats induced by Na-sulfacetylthiazole.
    Okano K; Nakai R; Tomori T; Yoshikawa M
    Endocrinol Jpn; 1978 Dec; 25(6):553-9. PubMed ID: 751801
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
    Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Nephron; 1976; 16(5):359-70. PubMed ID: 1264309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The investigation and treatment of renal bone disease.
    Catto GR; MacLeod M
    Am J Med; 1976 Jul; 61(1):64-73. PubMed ID: 937372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients.
    Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.